Characterization of pegylated (40kDa) interferon alfa-2A (Pegasys™) in the elderly.

被引：0
|
作者：
Martin, NE
Modi, MW
Reddy, KR
机构：
[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[2] Univ Miami, Miami, FL 33152 USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
755
引用
收藏
页码：348A / 348A
页数：1
相关论文
共 50 条
  • [41] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on Rebetron™ therapy:: A preliminary report of a randomized, multicenter efficacy and safety study
    Herrine, SK
    Brown, R
    Esposito, S
    Lok, A
    Galati, JS
    Bernstein, DE
    Campagna, J
    Pappas, SC
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A384 - A384
  • [42] Will pegylated interferon alfa-2a replace hydroxyurea in the treatment of Vaquez polyglobulia?
    Thepot, Sylvain
    [J]. HEMATOLOGIE, 2008, 14 (06): : 400 - 401
  • [43] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    [J]. HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [44] Peginterferon alfa-2a (Pegasys) for chronic hepatitis C
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1151): : 19 - 20
  • [45] Characterisation of interferon alfa-2A and pegylated interferon alfa-2A in combination with ribavirin, mycophenolic acid or VX-497 as inhibitors of HCV replicon replication
    Wilkinson, TCI
    Laxton, C
    Hobbs, E
    Bartenschlager, R
    Graves, M
    Devos, R
    Najera, I
    [J]. JOURNAL OF HEPATOLOGY, 2001, 34 : 117 - 118
  • [46] Enhanced pharmacokinetics (PK) and pharmacodynamics (PD) of peginterferon alfa-2a (40KD) (PEGASYS®) vs conventional interferon alfa-2a in HBeAg-positive chronic hepatitis B (CHB)
    Choudhury, S
    Wang, YJ
    Thongasawat, S
    Minde, Z
    Chan, WY
    Piratvisuth, T
    Yuan, R
    [J]. ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER MEETING 2002, 2002, : 95 - 100
  • [47] Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C
    Liu, Chen-Hua
    Liang, Cheng-Chao
    Liu, Chun-Jen
    Lin, Jou-Wei
    Chen, Shih-I
    Hung, Peir-Haur
    Tsai, Hung-Bin
    Lai, Ming-Yang
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) : 541 - 549
  • [48] PEGYLATED INTERFERON ALFA-2A MONOTHERAPY FOR HEMODIALYSIS PATIENTS WITH ACUTE HEPATITIS C
    Liu, Chen-Hua
    Liang, Cheng-Chao
    Liu, Chun-Jen
    Hsu, Shih-Jer
    Chen, Shih-I
    Tsai, Hung-Bin
    Hung, Peir-Haur
    Lin, Jou-Wei
    Lai, Ming-Yang
    Chen, Pei-Jer
    Chen, Jun-Herng
    Chen, Ding-Shinn
    Kao, Jia-Horng
    [J]. HEPATOLOGY, 2009, 50 (04) : 692A - 692A
  • [49] THE PHARMACOLOGY OF INTERFERON ALFA-2A
    GAUCI, L
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 93 (04) : 551 - 551
  • [50] The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naive patients infected with hcv: Phase 3 results
    Marcellin, P.
    Lurie, Y.
    Rodrigues-Torres, M.
    Chasen, R.
    Xu, Y.
    Murphy, B.
    [J]. JOURNAL OF HEPATOLOGY, 2007, 46 : S7 - S7
12345